• See Also
  1. Chemotherapy
  2. Alkylating Agent
  • Indications
  1. FDA Approved
    1. Chronic Lymphocytic Leukemia (CLL)
    2. Non-Hodgkin Lymphoma
  2. Off-label
    1. Mantle Cell Lymphoma
    2. Multiple Myeloma
    3. B-Cell Non-Hodgkin Lymphoma
    4. Waldenstrom Macroglobulinemia
  • Mechanism
  1. See Alkylating Agent
  2. Nitrogen Mustard derived antineoplastic Alkylating Agent
  3. Mechlorethamine derivative with alkylator and antimetabolite properties
    1. Alkylating group (cross-links DNA)
    2. Purine Analogue (DNA, RNA and Protein synthesis inhibitor)
    3. Vesicant
  • Medications
  1. Treanda 25 mg and 100 mg vials containing powder for preparation of IV solution
  2. Bendeka 100 mg/4 ml IV solution
  • Dosing
  1. See other references for disease specific dosing protocols
  • Pharmacokinetics
  1. Hepatic metabolism to both active and inactive metabolites
  • Safety
  1. Avoid in Lactation
  2. Avoid in pregnancy (contraindicated in all trimesters)
    1. Teratogenic and adverse outcomes
    2. Use reliable Contraception
  3. Monitoring
    1. Complete Blood Count
    2. Renal Function tests
  • Adverse Effects
  1. Bone Marrow Suppression
  2. Nephrotoxicity
  3. Hepatotoxicity
  4. Hypersensitivity and Drug Reactions
    1. Anaphylaxis
    2. Stevens-Johnson Syndrome
    3. Toxic Epidermal Necrolysis
    4. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome)
  • Resources
  1. Bendamustine (Treanda)
    1. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39d53698-57fa-7c99-fc5b-f52a55684826
  2. Bendamustine (Bendeka)
    1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ace9a43b-f9bd-4896-abfe-0ef4fec67ddf